Labetalol injection
 Labetalol Injection USP

drug-information.ru

|Labetalol injection Labetalol Injection USP

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Labetalol


Generic Name: Labetalol hydrochloride
Dosage Form: Injection

Rx only

Labetalol Description

Labetalol HCl is an adrenergic receptor blocking agent that has both selective alpha1- and nonselective beta-adrenergic receptor blocking actions in a single substance.

Labetalol HCl is a racemate, chemically designated as 5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl]salicylamide monohydrochloride, and has the following structural formula:

Labetalol HCl has the molecular formula C19H24N2O3• HCl and a molecular weight of 364.87. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R, R´ stereoisomer, makes up 25% of racemic Labetalol.

Labetalol HCl is a white or off-white crystalline powder, soluble in water.

Labetalol HCl Injection is a clear, colorless to light yellow aqueous sterile isotonic solution for intravenous injection. It has a pH range of 3.0 to 4.5. Each mL contains 5 mg Labetalol HCl, USP, 45 mg anhydrous dextrose; 0.10 mg edetate disodium; 0.80 mg methylparaben and 0.10 mg propylparaben as preservatives; citric acid, anhydrous and sodium hydroxide, as necessary, to bring the solution into the pH range.

Labetalol - Clinical Pharmacology

Labetalol combines both selective, competitive alpha1-adrenergic blocking and nonselective, competitive beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous administration, respectively. Beta2-agonist activity has been demonstrated in animals with minimal beta1-agonist (ISA) activity detected. In animals, at doses greater than those required for alpha- or betaadrenergic blockade, a membrane-stabilizing effect has been demonstrated.

Pharmacodynamics

The capacity of Labetalol to block alpha-receptors in man has been demonstrated by attenuation of the pressor effect of phenylephrine and by a significant reduction of the pressor response caused by immersing the hand in ice-cold water (“cold-pressor test”). Labetalol beta1-receptor blockade in man was demonstrated by a small decrease in the resting heart rate, attenuation of tachycardia produced by isoproterenol or exercise, and by attenuation of the reflex tachycardia to the hypotension produced by amyl nitrite. Beta2-receptor blockade was demonstrated by inhibition of the isoproterenol-induced fall in diastolic blood pressure. Both the alpha- and beta-blocking actions of orally administered Labetalol HCl contribute to a decrease in blood pressure in hypertensive patients. Labetalol consistently, in dose-related fashion, blunted increases in exercise-induced blood pressure and heart rate, and in their double product. The pulmonary circulation during exercise was not affected by Labetalol HCl dosing.

Single oral doses of Labetalol HCl administered to patients with coronary artery disease had no significant effect on sinus rate, intraventricular conduction, or QRS duration. The AV conduction time was modestly prolonged in 2 of 7 patients. In another study, intravenous Labetalol slightly prolonged AV nodal conduction time and atrial effective refractory period with only small changes in heart rate. The effects on AV nodal refractoriness were inconsistent.

Labetalol produces dose-related falls in blood pressure without reflex tachycardia and without significant reduction in heart rate, presumably through a mixture of its alpha-blocking and beta-blocking effects. Hemodynamic effects are variable with small nonsignificant changes in cardiac output seen in some studies but not others, and small decreases in total peripheral resistance. Elevated plasma renins are reduced.

Doses of Labetalol HCl that controlled hypertension did not affect renal function in mildly to severely hypertensive patients with normal renal function.

Due to the alpha1-receptor blocking activity of Labetalol, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension can occur. During dosing with intravenous Labetalol HCl, the contribution of the postural component should be considered when positioning patients for treatment, and patients should not be allowed to move to an erect position unmonitored until their ability to do so is established.

In a clinical pharmacologic study in severe hypertensives, an initial 0.25 mg/kg injection of Labetalol HCl, administered to patients in the supine position, decreased blood pressure by an average of 11/7 mmHg. Additional injections of 0.5 mg/kg at 15-minute intervals up to a total cumulative dose of 1.75 mg/kg of Labetalol HCl caused further dose-related decreases in blood pressure. Some patients required cumulative doses of up to 3.25 mg/kg. The maximal effect of each dose level occurred within 5 minutes. Following discontinuation of intravenous treatment with Labetalol HCl, the blood pressure rose gradually and progressively, approaching pretreatment baseline values within an average of 16 to 18 hours in the majority of patients.

Similar results were obtained in the treatment of patients with severe hypertension requiring urgent blood pressure reduction with an initial dose of 20 mg (which corresponds to 0.25 mg/kg for an 80 kg patient) followed by additional doses of either 40 or 80 mg at 10-minute intervals to achieve the desired effect or up to a cumulative dose of 300 mg.

Labetalol HCl administered as a continuous intravenous infusion, with a mean dose of 136 mg (27 to 300 mg) over a period of 2 to 3 hours (mean of 2 hours and 39 minutes) lowered the blood pressure by an average of 60/35 mmHg.

Exacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation, headache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors.

Although beta-adrenergic receptor blockade is useful in the treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen AV block by preventing the necessary facilitating effects of sympathetic activity on conduction. Beta2-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients.

Pharmacokinetics and Metabolism

Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg. The plasma half-life of Labetalol following oral administration is about 6 to 8 hours. In patients with decreased hepatic or renal function, the elimination half-life of Labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased due to decreased “first-pass” metabolism.

The metabolism of Labetalol is mainly through conjugation to glucuronide metabolities. These metabolites are present in plasma and are excreted in the urine and, via the bile, into the feces. Approximately 55% to 60% of a dose appears in the urine as conjugates or unchanged Labetalol within the first 24 hours of dosing.

Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the bloodbrain barrier in animal studies. Labetalol is approximately 50% protein bound. Neither hemodialysis nor peritoneal dialysis removes a significant amount of Labetalol from the general circulation (<1%).

Indications and Usage for Labetalol

Labetalol HCl Injection is indicated for control of blood pressure in severe hypertension.

Contraindications

Labetalol HCl Injection is contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product.

Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma. (see WARNINGS).

Warnings

Hepatic Injury

Severe hepatocellular injury, confirmed by rechallenge in at least one case, occurs rarely with Labetalol therapy. The hepatic injury is usually reversible, but hepatic necrosis and death have been reported. Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology. Similar hepatic events have been reported with a related research compound, dilevalol HCl, including two deaths. Dilevalol HCl is one of the four isomers of Labetalol HCl. Thus, for patients taking Labetalol, periodic determination of suitable hepatic laboratory tests would be appropriate. Laboratory testing should also be done at the very first symptom or sign of liver dysfunction (e.g. pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness, or unexplained “flu-like” symptoms). If the patient has jaundice or laboratory evidence of liver injury or jaundice, Labetalol should be stopped and not restarted.

Cardiac Failure

Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure. Betablockade carries a potential hazard of further depressing myocardial contractility and precipitating more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, Labetalol can be used with caution in patients with a history of heart failure who are well compensated. Congestive heart failure has been observed in patients receiving Labetalol HCl. Labetalol does not abolish the inotropic action of digitalis on heart muscle.

In Patients Without a History of Cardiac Failure

In patients with latent cardiac insufficiency, continued depression of the myocardium with beta-blocking agents over a period of time can lead, in some cases, to cardiac failure. At the first sign of symptom of impending cardiac failure, patients should be fully digitalized and/or be given a diuretic, and the response observed closely. If cardiac failure continues, despite adequate digitalization and diuretic, Labetalol therapy should be withdrawn (gradually if possible).

Ischemic Heart Disease

Angina pectoris has not been reported upon Labetalol discontinuation. However, following abrupt cessation of therapy with some beta-blocking agents in patients with coronary artery disease, exacerbations of angina pectoris and, in some cases, myocardial infarction have been reported. Therefore, such patients should be cautioned against interruption of therapy without the physician’s advice. Even in the absence of overt angina pectoris, when discontinuation of Labetalol is planned, the patient should be carefully observed and should be advised to limit physical activity. If angina markedly worsens or acute coronary insufficiency develops, Labetalol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken.

Nonallergic Bronchospasm (e.g. chronic bronchitis and emphysema)

Since Labetalol HCl injection at the usual intravenous therapeutic doses has not been studied in patients with nonallergic bronchospastic disease, it should not be used in such patients.

Pheochromocytoma

Intravenous Labetalol has been shown to be effective in lowering the blood pressure and relieving symptoms in patients with pheochromocytoma; higher than usual doses may be required. However, paradoxical hypertensive responses have been reported in a few patients with this tumor; therefore, use caution when administering Labetalol to patients with pheochromocytoma.

Diabetes Mellitus and Hypoglycemia

Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to hyperglycemia; it may therefore be necessary to adjust the dose of antidiabetic drugs.

Major Surgery

The necessity or desirability of withdrawing beta-blocking therapy prior to major surgery is controversial. Protracted severe hypotension and difficulty in restarting or maintaining a heartbeat have been reported with beta-blockers. The effect of Labetalol alpha-adrenergic activity has not been evaluated in this setting.

Several deaths have occurred when Labetalol HCl injection was used during surgery (including when used in cases to control bleeding).

A synergism between Labetalol and halothane anesthesia has been shown (see PRECAUTIONS - DRUG INTERACTIONS).

Rapid Decreases of Blood Pressure

Caution must be observed when reducing severely elevated blood pressure. A number of adverse reactions, including cerebral infarction, optic nerve infarction, angina, and ischemic changes in the electrocardiogram, have been reported with other agents when severely elevated blood pressure was reduced over time courses of several hours to as long as 1 or 2 days. The desired blood pressure lowering should therefore be achieved over as long a period of time as is compatible with the patient’s status.

Precautions

General

Impaired Hepatic Function

Labetalol injection should be used with caution in patients with impaired hepatic function since metabolism of the drug may be diminished.

Hypotension

Symptomatic postural hypotension (incidence 58%) is likely to occur if patients are tilted or allowed to assume the upright position within 3 hours of receiving Labetalol HCl injection. Therefore, the patient’s ability to tolerate an upright position should be established before permitting any ambulation.

Following Coronary Artery Bypass Surgery

In one uncontrolled study, patients with low cardiac indices and elevated systemic vascular resistance following intravenous Labetalol experienced significant declines in cardiac output with little change in systemic vascular resistance. One of these patients developed hypotension following Labetalol HCl treatment. Therefore use of Labetalol should be avoided in such patients.

High-Dose Labetalol HCl

Administration of up to 3 g/d as an infusion for up to 2 to 3 days has been anecdotally reported; several patients experienced hypotension or bradycardia (see DOSAGE AND ADMINISTRATION).

Jaundice or Hepatic Dysfunction

(see WARNINGS).

Information for Patients

The following information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. During and immediately following (for up to 3 hours) Labetalol HCl injection, the patient should remain supine. Subsequently, the patient should be advised on how to proceed gradually to become ambulatory, and should be observed at the time of first ambulation.

When the patient is started on oral Labetalol HCl tablets following adequate control of blood pressure with Labetalol HCl injection, appropriate directions for titration of dosage should be provided.

Laboratory Test

Routine laboratory tests are ordinarily not required before or after intravenous Labetalol. In patients with concomitant illnesses, such as impaired renal function, appropriate tests should be done to monitor these conditions.

Drug Interactions

Since Labetalol HCl injection may be administered to patients already being treated with other medications, including other antihypertensive agents, careful monitoring of these patients is necessary to detect and treat promptly any undesired effect from concomitant administration.

In one survey, 2.3% of patients taking Labetalol orally in combination with tricyclic antidepressants experienced tremor as compared to 0.7% reported to occur with Labetalol alone. The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded.

Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.

Cimetidine has been shown to increase the bioavailability of Labetalol administered orally. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of Labetalol, special care should be used in establishing the dose required for blood pressure control in such patients.

Synergism has been shown between halothane anesthesia and intravenously administered Labetalol. During controlled hypotensive anesthesia using Labetalol in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving Labetalol.

Labetalol blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect. If Labetalol is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.

Care should be taken if Labetalol is used concomitantly with calcium antagonists of the verapamil type.

When drug products that are alkaline, such as furosemide, have been administered in combination with Labetalol, a white precipitate has been noted. Therefore, these drugs should not be administered in the same infusion line.

Risk of Anaphylactic Reaction - While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

Drug/Laboratory Test Interactions

The presence of Labetalol metabolities in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic acid (VMA) when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with Labetalol, a specific method, such as a highperformance liquid chromatographic assay with solid phase extraction (e.g. J Chromatogr. 385:241, 1987) should be employed in determining levels of catecholamines.

Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A® (thin-layer chromatographic assay) and Emit-d.a.u.® (radioenzymatic assay). When patients being treated with Labetalol have a positive urine test for amphetamine using these techniques, confirmation should be made by using more specific methods, such as a gas chromatographic-mass spectrometer technique.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term oral dosing studies with Labetalol for 18 months in mice and for 2 years in rats showed no evidence of carcinogenesis. Studies with Labetalol, using dominant lethal assays in rats and mice, and exposing microorganisms according to modified Ames tests, showed no evidence of mutagenesis.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Teratogenic studies have been performed with Labetalol in rats and rabbits at oral doses up to approximately 6 and 4 times the maximum recommended human dose (MRHD), respectively. No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with Labetalol in rabbits at intravenous doses up to 1.7 times the MRHD revealed no evidence of drug-related harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects -Hypotension, bradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with Labetalol for hypertension during pregnancy. Oral administration of Labetalol to rats during late gestation through weaning at doses of 2 to 4 times the MRHD caused a decrease in neonatal survival.

NonTeratogenic Effects

Hypotension, bradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with Labetalol for hypertension during pregnancy. Oral administration of Labetalol to rats during late gestation through weaning at doses of 2 to 4 times the MRHD caused a decrease in neonatal survival.

Labor and Delivery

Labetalol given to pregnant women with hypertension did not appear to affect the usual course of labor and delivery.

Nursing Mothers

Small amounts of Labetalol (approximately 0.004% of the maternal dose) are excreted in human milk. Caution should be exercised when Labetalol HCl injection is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Adverse Reactions

Labetalol HCl Injection is usually well tolerated. Most adverse effects have been mild and transient and, in controlled trials involving 92 patients, did not require Labetalol withdrawal. Symptomatic postural hypotension (incidence 58%) is likely to occur if patients are tilted or allowed to assume the upright position within 3 hours of receiving Labetalol HCl injection. Moderate hypotension occurred in 1 of 100 patients while supine. Increased sweating was noted in 4 of 100 patients, and flushing occurred in 1 of 100 patients.

The following also were reported with Labetalol HCl injection with the incidence per 100 patients as noted:

Cardiovascular System -Ventricular arrhythmia in 1.

Central and Peripheral Nervous Systems -Dizziness in 9; tingling of the scalp/skin 7; hypoesthesia (numbness) and vertigo, 1 each.

Gastrointestinal System -Nausea in 13; vomiting 4; dyspepsia and taste distortion, 1 each.

Metabolic Disorders -Transient increases in blood urea nitrogen and serum creatinine levels occurred in 8 of 100 patients; these were associated with drops in blood pressure, generally in patients with prior renal insufficiency.

Psychiatric Disorders -Somnolence/yawning in 3.

Respiratory System -Wheezing in 1.

Skin -Pruritus in 1.

The incidence of adverse reactions depends upon the dose of Labetalol HCl. The largest experience is with oral Labetalol HCl (see oral Labetalol HCl product information for details).

Certain of the side effects increased with increasing oral dose as shown in the table below which depicts the entire U.S. therapeutic trials data base for adverse reactions that are clearly or possibly dose related.

Labetalol HCl

In addition, a number of other less common adverse events have been reported:

Cardiovascular -Hypotension, and rarely, syncope, bradycardia, heart block.

Liver and Biliary System -Hepatic necrosis, hepatitis, cholestatic jaundice, elevated liver function tests.

Hypersensitivity -Rare reports of hypersensitivity (e.g. rash, urticaria, pruritus, angioedema, dyspnea) and anaphylactoid reactions.

The oculomucocutaneous syndrome associated with the betablocker practolol has not been reported with Labetalol HCl during investigational use and extensive foreign marketing experience.

CLINICAL LABORATORY TESTS

Among patients dosed with oral Labetalol, there have been reversible increases of serum transaminases in 4% of patients tested, and more rarely, reversible increases in blood urea.

Overdosage

Overdosage with Labetalol HCl injection causes excessive hypotension that is posture sensitive, and sometimes, excessive bradycardia. Patients should be placed supine and their legs raised if necessary to improve the blood supply to the brain. If overdosage with Labetalol HCl follows oral ingestion, gastric lavage or pharmacologically induced emesis (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. The following additional measures should be employed if necessary: Excessive bradycardia – administer atropine or epinephrine. Cardiac failure - administer a digitalis glycoside and a diuretic. Dopamine or dobutamine may also be useful. Hypotension -administer vasopressors, e.g. norepinephrine. There is pharmacological evidence that norepinephrine may be the drug of choice. Bronchospasm - administer epinephrine and/or an aerosolized beta2-agonist. Seizures – administer diazepam.

In severe beta-blocker overdose resulting in hypotension and/or bradycardia, glucagon has been shown to be effective when administered in large doses (5 to 10 mg rapidly over 30 seconds, followed by continuous infusion of 5 mg/hr that can be reduced as the patient improves).

Neither hemodialysis nor peritoneal dialysis removes a significant amount of Labetalol from the general circulation (<1%).

The oral LD50 value of Labetalol HCl in the mouse is approximately 600 mg/kg and in the rat is greater than 2 g/kg. The intravenous LD50 in these species is 50 to 60 mg/kg.

Labetalol Dosage and Administration

Labetalol HCl Injection is intended for intravenous use in hospitalized patients. DOSAGE MUST BE INDIVIDUALIZED depending upon the severity of hypertension and the response of the patient during dosing.

Patients should always be kept in a supine position during the period of intravenous drug administration. A substantial fall in blood pressure on standing should be expected in these patients. The patient’s ability to tolerate an upright position should be established before permitting any ambulation, such as using toilet facilities.

Either of two methods of administration of Labetalol HCl injection may be used:

a) repeated intravenous injections. b) slow continuous infusion.

Repeated Intravenous Injection

Initially, Labetalol HCl injection should be given in a dose of 20 mg Labetalol HCl (which corresponds to 0.25 mg/kg for an 80 kg patient) by slow intravenous injection over a 2-minute period.

Immediately before the injection and at 5 and 10 minutes after injection, supine blood pressure should be measured to evaluate response. Additional injections of 40 mg or 80 mg can be given at 10-minute intervals until a desired supine blood pressure is achieved or a total of 300 mg Labetalol HCl has been injected. The maximum effect usually occurs within 5 minutes of each injection.

Slow Continuous Infusion

Labetalol HCl Injection is prepared for continuous intravenous infusion by diluting the vial contents with commonly used intravenous fluids (see below). Examples of methods of preparing the infusion solution are:

The contents of either two 20 mL vials (40 mL), or one 40 mL vial, are added to 160 mL of a commonly used intravenous fluid such that the resultant 200 mL of solution contains 200 mg of Labetalol HCl, 1 mg/mL. The diluted solution should be administered at a rate of 2 mL/min to deliver 2 mg/min.

Alternatively, the contents of either two 20 mL vials (40 mL), or one 40 mL vial, of Labetalol HCl injection are added to 250 mL of a commonly used intravenous fluid. The resultant solution will contain 200 mg of Labetalol HCl, approximately 2 mg/3 mL. The diluted solution should be administered at a rate of 3 mL/min to deliver approximately 2 mg/min.

The rate of infusion of the diluted solution may be adjusted according to the blood pressure response, at the discretion of the physician. To facilitate a desired rate of infusion, the diluted solution can be infused using a controlled administration mechanism, e.g., graduated burette or mechanically driven infusion pump.

Since the half-life of Labetalol is 5 to 8 hours, steady-state blood levels (in the face of a constant rate of infusion) would not be reached during the usual infusion time period. The infusion should be continued until a satisfactory response is obtained and should then be stopped and oral Labetalol HCl started (see below). The effective intravenous dose is usually in the range of 50 to 200 mg. A total dose of up to 300 mg may be required in some patients.

Blood Pressure Monitoring

The blood pressure should be monitored during and after completion of the infusion or intravenous injection. Rapid or excessive falls in either systolic or diastolic blood pressure during intravenous treatment should be avoided. In patients with excessive systolic hypertension, the decrease in systolic pressure should be used as indicator of effectiveness in addition to the response of the diastolic pressure.

Initiation of Dosing with Oral Labetalol HCl

Subsequent oral dosing with Labetalol hydrochloride tablets should begin when it has been established that the supine diastolic pressure has begun to rise. The recommended initial dose is 200 mg, followed in 6 to 12 hours by an additional dose of 200 or 400 mg, depending on the blood pressure response. Thereafter, inpatient titration with Labetalol hydrochloride tablets may proceed as follows:

* If needed, the total daily dose may be given in three divided doses.

While in the hospital, the dosage of Labetalol hydrochloride tablets may be increased at 1 day intervals to achieve the desired blood pressure reduction.

For subsequent outpatient titration or maintenance dosing see Labetalol hydrochloride tablets product information DOSAGE AND ADMINISTRATION for additional recommendations.

Compatibility with Commonly Used Intravenous Fluids

Labetalol HCl Injection was tested for compatibility with commonly used intravenous fluids at final concentrations of 1.25 mg to 3.75 mg Labetalol HCl per mL of the mixture. Labetalol HCl Injection was found to be compatible with and stable (for 24 hours refrigerated or at room temperature) in mixtures with the following solutions:

Ringers Injection, USP

Lactated Ringers Injection, USP

5% Dextrose and Ringers Injection

5% Lactated Ringers and 5% Dextrose Injection

5% Dextrose Injection, USP

0.9% Sodium Chloride Injection, USP

5% Dextrose and 0.2% Sodium Chloride Injection, USP

2.5% Dextrose and 0.45% Sodium Chloride Injection, USP

5% Dextrose and 0.9% Sodium Chloride Injection, USP

5% Dextrose and 0.33% Sodium Chloride Injection, USP

Labetalol HCl Injection was NOT compatible with 5% Sodium Bicarbonate Injection, USP. Care should be taken when administering alkaline drugs, including furosemide, in combination with Labetalol. Compatibility should be assured prior to administering these drugs together.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

How is Labetalol Supplied

Labetalol Hydrochloride Injection, USP 5 mg/mL is available in a 20 mL multidose vial (NDC 61703-233-47) individually packaged and in a 40 mL multidose vial (NDC 61703-233-48) individually packaged.

Store between 2° and 30°C (36° and 86°F). Protect from freezing and light.

Manufactured for:

Mayne Pharma (USA) Inc.

Paramus, NJ  07652

By: Mayne Pharma (PR) Inc.

Aguadilla, Puerto Rico 00604

Rev. February 2004         PI040/KB


Labetalol Hydrochloride (Labetalol Hydrochloride)
PRODUCT INFO
Product Code 61703-233 Dosage Form INJECTION, SOLUTION
Route Of Administration INTRAVENOUS DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Labetalol Hydrochloride (Labetalol) Active 5 MILLIGRAM  In 1 MILLILITER
dextrose Inactive 45 MILLIGRAM  In 1 MILLILITER
edetate disodium Inactive 0.10 MILLIGRAM  In 1 MILLILITER
methylparaben Inactive 0.80 MILLIGRAM  In 1 MILLILITER
propylparaben Inactive 0.10 MILLIGRAM  In 1 MILLILITER
citric acid Inactive  
anhydrous hydroxide Inactive  
sodium hydroxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 61703-233-47 20 MILLILITER In 1 VIAL, MULTI-DOSE None
2 61703-233-48 40 MILLILITER In 1 VIAL, MULTI-DOSE None

Revised: 10/2006





Where can I get more information about Labetalol injection Labetalol Injection USP ? We recommend to use www.Drugs.com

Typical mistypes for Labetalol injection Labetalol Injection USP
kabetalol injection labetalol injection usp, pabetalol injection labetalol injection usp, oabetalol injection labetalol injection usp, lzbetalol injection labetalol injection usp, lsbetalol injection labetalol injection usp, lwbetalol injection labetalol injection usp, lqbetalol injection labetalol injection usp, lavetalol injection labetalol injection usp, lanetalol injection labetalol injection usp, lahetalol injection labetalol injection usp, lagetalol injection labetalol injection usp, labwtalol injection labetalol injection usp, labstalol injection labetalol injection usp, labdtalol injection labetalol injection usp, labrtalol injection labetalol injection usp, lab4talol injection labetalol injection usp, lab3talol injection labetalol injection usp, laberalol injection labetalol injection usp, labefalol injection labetalol injection usp, labegalol injection labetalol injection usp, labeyalol injection labetalol injection usp, labe6alol injection labetalol injection usp, labe5alol injection labetalol injection usp, labetzlol injection labetalol injection usp, labetslol injection labetalol injection usp, labetwlol injection labetalol injection usp, labetqlol injection labetalol injection usp, labetakol injection labetalol injection usp, labetapol injection labetalol injection usp, labetaool injection labetalol injection usp, labetalil injection labetalol injection usp, labetalkl injection labetalol injection usp, labetalll injection labetalol injection usp, labetalpl injection labetalol injection usp, labetal0l injection labetalol injection usp, labetal9l injection labetalol injection usp, labetalok injection labetalol injection usp, labetalop injection labetalol injection usp, labetaloo injection labetalol injection usp, labetalol unjection labetalol injection usp, labetalol jnjection labetalol injection usp, labetalol knjection labetalol injection usp, labetalol onjection labetalol injection usp, labetalol 9njection labetalol injection usp, labetalol 8njection labetalol injection usp, labetalol ibjection labetalol injection usp, labetalol imjection labetalol injection usp, labetalol ijjection labetalol injection usp, labetalol ihjection labetalol injection usp, labetalol inhection labetalol injection usp, labetalol innection labetalol injection usp, labetalol inmection labetalol injection usp, labetalol inkection labetalol injection usp, labetalol iniection labetalol injection usp, labetalol inuection labetalol injection usp, labetalol injwction labetalol injection usp, labetalol injsction labetalol injection usp, labetalol injdction labetalol injection usp, labetalol injrction labetalol injection usp, labetalol inj4ction labetalol injection usp, labetalol inj3ction labetalol injection usp, labetalol injextion labetalol injection usp, labetalol injevtion labetalol injection usp, labetalol injeftion labetalol injection usp, labetalol injedtion labetalol injection usp, labetalol injecrion labetalol injection usp, labetalol injecfion labetalol injection usp, labetalol injecgion labetalol injection usp, labetalol injecyion labetalol injection usp, labetalol injec6ion labetalol injection usp, labetalol injec5ion labetalol injection usp, labetalol injectuon labetalol injection usp, labetalol injectjon labetalol injection usp, labetalol injectkon labetalol injection usp, labetalol injectoon labetalol injection usp, labetalol inject9on labetalol injection usp, labetalol inject8on labetalol injection usp, labetalol injectiin labetalol injection usp, labetalol injectikn labetalol injection usp, labetalol injectiln labetalol injection usp, labetalol injectipn labetalol injection usp, labetalol injecti0n labetalol injection usp, labetalol injecti9n labetalol injection usp, labetalol injectiob labetalol injection usp, labetalol injectiom labetalol injection usp, labetalol injectioj labetalol injection usp, labetalol injectioh labetalol injection usp, labetalol injection kabetalol injection usp, labetalol injection pabetalol injection usp, labetalol injection oabetalol injection usp, labetalol injection lzbetalol injection usp, labetalol injection lsbetalol injection usp, labetalol injection lwbetalol injection usp, labetalol injection lqbetalol injection usp, labetalol injection lavetalol injection usp, labetalol injection lanetalol injection usp, labetalol injection lahetalol injection usp, labetalol injection lagetalol injection usp, labetalol injection labwtalol injection usp, labetalol injection labstalol injection usp, labetalol injection labdtalol injection usp, labetalol injection labrtalol injection usp, labetalol injection lab4talol injection usp, labetalol injection lab3talol injection usp, labetalol injection laberalol injection usp, labetalol injection labefalol injection usp, labetalol injection labegalol injection usp, labetalol injection labeyalol injection usp, labetalol injection labe6alol injection usp, labetalol injection labe5alol injection usp, labetalol injection labetzlol injection usp, labetalol injection labetslol injection usp, labetalol injection labetwlol injection usp, labetalol injection labetqlol injection usp, labetalol injection labetakol injection usp, labetalol injection labetapol injection usp, labetalol injection labetaool injection usp, labetalol injection labetalil injection usp, labetalol injection labetalkl injection usp, labetalol injection labetalll injection usp, labetalol injection labetalpl injection usp, labetalol injection labetal0l injection usp, labetalol injection labetal9l injection usp, labetalol injection labetalok injection usp, labetalol injection labetalop injection usp, labetalol injection labetaloo injection usp, labetalol injection labetalol unjection usp, labetalol injection labetalol jnjection usp, labetalol injection labetalol knjection usp, labetalol injection labetalol onjection usp, labetalol injection labetalol 9njection usp, labetalol injection labetalol 8njection usp, labetalol injection labetalol ibjection usp, labetalol injection labetalol imjection usp, labetalol injection labetalol ijjection usp, labetalol injection labetalol ihjection usp, labetalol injection labetalol inhection usp, labetalol injection labetalol innection usp, labetalol injection labetalol inmection usp, labetalol injection labetalol inkection usp, labetalol injection labetalol iniection usp, labetalol injection labetalol inuection usp, labetalol injection labetalol injwction usp, labetalol injection labetalol injsction usp, labetalol injection labetalol injdction usp, labetalol injection labetalol injrction usp, labetalol injection labetalol inj4ction usp, labetalol injection labetalol inj3ction usp, labetalol injection labetalol injextion usp, labetalol injection labetalol injevtion usp, labetalol injection labetalol injeftion usp, labetalol injection labetalol injedtion usp, labetalol injection labetalol injecrion usp, labetalol injection labetalol injecfion usp, labetalol injection labetalol injecgion usp, labetalol injection labetalol injecyion usp, labetalol injection labetalol injec6ion usp, labetalol injection labetalol injec5ion usp, labetalol injection labetalol injectuon usp, labetalol injection labetalol injectjon usp, labetalol injection labetalol injectkon usp, labetalol injection labetalol injectoon usp, labetalol injection labetalol inject9on usp, labetalol injection labetalol inject8on usp, labetalol injection labetalol injectiin usp, labetalol injection labetalol injectikn usp, labetalol injection labetalol injectiln usp, labetalol injection labetalol injectipn usp, labetalol injection labetalol injecti0n usp, labetalol injection labetalol injecti9n usp, labetalol injection labetalol injectiob usp, labetalol injection labetalol injectiom usp, labetalol injection labetalol injectioj usp, labetalol injection labetalol injectioh usp, labetalol injection labetalol injection ysp, labetalol injection labetalol injection hsp, labetalol injection labetalol injection jsp, labetalol injection labetalol injection isp, labetalol injection labetalol injection 8sp, labetalol injection labetalol injection 7sp, labetalol injection labetalol injection uap, labetalol injection labetalol injection uzp, labetalol injection labetalol injection uxp, labetalol injection labetalol injection udp, labetalol injection labetalol injection uep, labetalol injection labetalol injection uwp, labetalol injection labetalol injection uso, labetalol injection labetalol injection usl, labetalol injection labetalol injection us-, labetalol injection labetalol injection us0, abetalol injection labetalol injection usp, lbetalol injection labetalol injection usp, laetalol injection labetalol injection usp, labtalol injection labetalol injection usp, labealol injection labetalol injection usp, labetlol injection labetalol injection usp, labetaol injection labetalol injection usp, labetall injection labetalol injection usp, labetalo injection labetalol injection usp, labetalolinjection labetalol injection usp, labetalol njection labetalol injection usp, labetalol ijection labetalol injection usp, labetalol inection labetalol injection usp, labetalol injction labetalol injection usp, labetalol injetion labetalol injection usp, labetalol injecion labetalol injection usp, labetalol injecton labetalol injection usp, labetalol injectin labetalol injection usp, labetalol injectio labetalol injection usp, labetalol injection labetalol injection usp, labetalol injection labetalol injection usp, labetalol injection abetalol injection usp, labetalol injection lbetalol injection usp, labetalol injection laetalol injection usp, labetalol injection labtalol injection usp, labetalol injection labealol injection usp, labetalol injection labetlol injection usp, labetalol injection labetaol injection usp, labetalol injection labetall injection usp, labetalol injection labetalo injection usp, labetalol injection labetalolinjection usp, labetalol injection labetalol njection usp, labetalol injection labetalol ijection usp, labetalol injection labetalol inection usp, labetalol injection labetalol injction usp, labetalol injection labetalol injetion usp, labetalol injection labetalol injecion usp, labetalol injection labetalol injecton usp, labetalol injection labetalol injectin usp, labetalol injection labetalol injectio usp, labetalol injection labetalol injectionusp, labetalol injection labetalol injection sp, labetalol injection labetalol injection up, labetalol injection labetalol injection us, albetalol injection labetalol injection usp, lbaetalol injection labetalol injection usp, laebtalol injection labetalol injection usp, labtealol injection labetalol injection usp, labeatlol injection labetalol injection usp, labetlaol injection labetalol injection usp, labetaoll injection labetalol injection usp, labetallo injection labetalol injection usp, labetalo linjection labetalol injection usp, labetaloli njection labetalol injection usp, labetalol nijection labetalol injection usp, labetalol ijnection labetalol injection usp, labetalol inejction labetalol injection usp, labetalol injcetion labetalol injection usp, labetalol injetcion labetalol injection usp, labetalol injeciton labetalol injection usp, labetalol injectoin labetalol injection usp, labetalol injectino labetalol injection usp, labetalol injectio n labetalol injection usp, labetalol injection labetalol injection usp, labetalol injection l abetalol injection usp, labetalol injection albetalol injection usp, labetalol injection lbaetalol injection usp, labetalol injection laebtalol injection usp, labetalol injection labtealol injection usp, labetalol injection labeatlol injection usp, labetalol injection labetlaol injection usp, labetalol injection labetaoll injection usp, labetalol injection labetallo injection usp, labetalol injection labetalo linjection usp, labetalol injection labetaloli njection usp, labetalol injection labetalol nijection usp, labetalol injection labetalol ijnection usp, labetalol injection labetalol inejction usp, labetalol injection labetalol injcetion usp, labetalol injection labetalol injetcion usp, labetalol injection labetalol injeciton usp, labetalol injection labetalol injectoin usp, labetalol injection labetalol injectino usp, labetalol injection labetalol injectio nusp, labetalol injection labetalol injectionu sp, labetalol injection labetalol injection sup, labetalol injection labetalol injection ups, llabetalol injection labetalol injection usp, laabetalol injection labetalol injection usp, labbetalol injection labetalol injection usp, labeetalol injection labetalol injection usp, labettalol injection labetalol injection usp, labetaalol injection labetalol injection usp, labetallol injection labetalol injection usp, labetalool injection labetalol injection usp, labetaloll injection labetalol injection usp, labetalol injection labetalol injection usp, labetalol iinjection labetalol injection usp, labetalol innjection labetalol injection usp, labetalol injjection labetalol injection usp, labetalol injeection labetalol injection usp, labetalol injecction labetalol injection usp, labetalol injecttion labetalol injection usp, labetalol injectiion labetalol injection usp, labetalol injectioon labetalol injection usp, labetalol injectionn labetalol injection usp, labetalol injection labetalol injection usp, labetalol injection labetalol injection usp, labetalol injection llabetalol injection usp, labetalol injection laabetalol injection usp, labetalol injection labbetalol injection usp, labetalol injection labeetalol injection usp, labetalol injection labettalol injection usp, labetalol injection labetaalol injection usp, labetalol injection labetallol injection usp, labetalol injection labetalool injection usp, labetalol injection labetaloll injection usp, labetalol injection labetalol injection usp, labetalol injection labetalol iinjection usp, labetalol injection labetalol innjection usp, labetalol injection labetalol injjection usp, labetalol injection labetalol injeection usp, labetalol injection labetalol injecction usp, labetalol injection labetalol injecttion usp, labetalol injection labetalol injectiion usp, labetalol injection labetalol injectioon usp, labetalol injection labetalol injectionn usp, labetalol injection labetalol injection usp, labetalol injection labetalol injection uusp, labetalol injection labetalol injection ussp, labetalol injection labetalol injection uspp, etc.


© Copyright by drug-information.ru 2001-2012. All rights reserved